Publications by authors named "Michela Presti"
Article Synopsis
- The study examines the cardiometabolic effects of hypercalcemic primary hyperparathyroidism (HC-PHPT) compared to normocalcemic primary hyperparathyroidism (NC-PHPT) and controls.
- Patients with HC-PHPT exhibited significant cardiometabolic abnormalities, including higher glucose, cholesterol, and blood pressure levels, as well as more frequent cardiovascular events compared to both NC-PHPT patients and controls.
- The findings suggest that NC-PHPT does not show these cardiovascular issues, indicating that hypercalcemia may play a key role in the development of cardiometabolic disorders in HC-PHPT.
Pituitary hormones play a crucial role in regulating skeletal physiology, and skeletal fragility is a frequent complication of pituitary diseases. The ability to predict the risk of fracture events is crucial for guiding therapeutic decisions; however, in patients with pituitary diseases, fracture risk estimation is particularly challenging. Compared to primary osteoporosis, the evaluation of bone mineral density by dual X-ray absorptiometry is much less informative about fracture risk.
View Article and Find Full Text PDFContext: Chronic use of proton pump inhibitors (PPIs) has been associated with an increase in bone fragility. However, evidence on the effect of chronic PPI use on bone density is conflicting, and data on bone microarchitectural quality are scarce.
Objective: The primary aim of this study was to evaluate whether trabecular bone microarchitecture, assessed by trabecular bone score (TBS), is altered in chronic PPI users.